The North American deep brain stimulation device market size was estimated at USD 670 million in 2025 and is projected to be worth around USD 1,769.66 million by 2035, is projected to expand at a CAGR of 10.20% from 2026 to 2035. Rising Parkinson's disease prevalence and advanced healthcare infrastructure are driving the demand for the deep brain stimulation device market.

North America Deep Brain Stimulation Devices Market Statical Scope

The North American deep brain stimulation device market is growing due to the increasing burden of Parkinson's disease, and Alzheimers disease, epilepsy, and tremor across ageing populations. The region has high awareness among neurologists, strong and advanced healthcare infrastructure, with favourable reimbursement policies, supporting wider adoption of deep brain stimulation therapies.

Hospitals and neuroscience centres in the region are increasingly adopting minimally invasive neuromodulation procedures to reduce medication dependence. The emerging trends include the integration of adaptive and AI-enabled stimulation technologies that improve precision and patient outcomes. However, the high cost of devices and the risk of infection may restrain the growth of the market.

North America Deep Brain Stimulation Devices Market Share, By Product Outlook, 2025, (%)

• Single Channel DBS - Single Channel DBS leads the segment, with a share of 45%, driven by earlier adoption in standard deep brain stimulation procedures and cost-effective treatment options.
• Dual Channel DBS - Dual Channel DBS hold a significant portion, with a share of 55%, supported by improved therapeutic precision, advanced neuromodulation capabilities, and growing clinical preference for bilateral stimulation systems.

North America Deep Brain Stimulation Devices Market Share, By Application outlook, 2025, (%)

• Pain Management - Pain Management leads the segment, with a share of 10%, driven by the rising use of neuromodulation therapies for chronic pain conditions and preference for non-drug therapies.
• Epilepsy - Epilepsy holds a significant portion, with a share of 15%, supported by increasing adoption in drug-resistant epilepsy treatment, and strong neurology infrastructure supports deep brain stimulation adoption.
• Essential Tremor - Essential Tremor accounts for 45%, driven by an ageing population, high prevalence and strong clinical effectiveness of deep brain stimulation (DBS) in tremor control.

North America Deep Brain Stimulation Devices Market Share, By End Use Outlook, 2025, (%)

• Hospitals - Hospitals lead the segment, with a share of 60%, driven by advanced neurosurgical infrastructure, high procedure volumes and skilled specialists to deliver services.
• Neurology Clinics - Neurology Clinics hold a significant portion, with a share of 25%, supported by specialized neurological care, follow-up treatments and personalized therapy adjustment for neurological patients.
• Ambulatory Surgical Centers - Ambulatory Surgical Centers account for 10%, driven by growing minimally invasive procedures and cost effectiveness.
• Research Centers - Research Centers hold 5%, supported by government funded research, neuromodulation research and ongoing clinical trials.

Recent Developments in the Market

• In October 2025, Ampa raised $8.5 million to begin its transcranial magnetic stimulation (TMS) system in the United States to treat major depressive disorder
• (MDD). The aim of Ampa One is to provide practical, portable and affordable tools to clinicians to improve access to lifesaving technologies. Ampa One System received clearance from the United States Food and Drug Administration (FDA) in February 2025.

Competitive Landscape

• The competitive landscape of the North American deep brain stimulation device market is characterized by both well established and emerging players. Key Participants operating in the market include Medtronic plc, Boston Scientific Corporation, Abbott, Enteromedics, Cyberonics, St. Jude Medical, Inc., SceneRay, Neuropace, Zynex, Neuronetics, Beijing Pins, Functional Neuromodulation Ltd., and Neurosigma, Inc. The key companies are investing in advanced technologies to enhance user experience and improve patient outcomes. Another strategy being used is the collaboration of companies with neurology experts and healthcare institutions to validate the devices and increase the market reach of companies.
• Leading companies such as Medtronic, Boston Scientific, and Abbott are focusing on research and development to innovate and enhance the efficacy of their DBS devices.
• Medtronic is a dominant player in the North American Neuromodulation market. The company offers key products such as Percept PC / Percept RC and the Sensight Directional Lead System.
• Boston Scientific offers highly customizable current manipulation and expanding partnerships with advanced software companies. Key products include Vercise Genus Family (P16 & R16) and STIMVIEW XT.
• Abbott offers key products such as the Infinity DBS System and the Liberta RC.
• Emerging players such as Beijing Pins and SceneRay are gaining attention because they are focusing on niche markets and developing cost effective alternatives.

Segment Covered in the Report

By Product

• Single Channel
• Dual Channel

By Application

• Pain Management
• Epilepsy
• Essential Tremor
• Obsessive-compulsive Disorders (OCD)
• Depression
• Dystonia
• Parkinson's Disease
• Others

By End-use

• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centers
• Research Centers